Sebastian Brunemeier
Co-founder & General Partner @ Healthspan Capital
Oxford, United Kingdom
Sebastian Brunemeier is a seed investor at Healthspan Capital in Oxford focused on Biotechnology and Medical. Sebastian A. Brunemeier is a biotech VC and company builder focused on longevity & regenerative medicine. He is Co-Founder and General Partner of Healthspan Capital, and CEO & Founder of ImmuneAGE Bio. Previously he was Principal at Apollo Health Ventures, the largest longevity fund in the world, CIO and Co-Founder at Cambrian Biopharma,and Founder of Samsara Therapeutics. He was a DPhil (PhD) Clarendon Scholar in Biochemistry at the University of Oxford, a Fulbright Fellow, a Skaggs-Oxford Scholar at the Scripps Research Institute, and holds a dual MSc in Molecular Neuroscience and Biotech Business Management from University of Amsterdam.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Sebastian Brunemeier invests in
Stages Sebastian Brunemeier invests in
Countries Sebastian Brunemeier invests in
Investment Focus
Industry
- Biotechnology 3 (100%)
- Medical 1 (33%)
- Wellness 1 (33%)
- Biopharma 1 (33%)
- Health Care 1 (33%)
Stage
- Seed 1 (33%)
- Pre-Seed 1 (33%)
- Series A 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Jung+ Longevity
|
Jung+ operates in the biotechnology industry, focusing on translating the latest scientific advancements into products and technologies aimed at slowing aging and extending healthy lifespan. The company leverages a deep understanding of the 12 Hallmarks of Aging, a scientific framework that maps the root causes of biological aging, to develop itsTotal Longevity System™. This system is designed to offer long-term, synergistic effects to users, incorporating various products engineered for enhancing lifespan and health. Jung+ is committed to bringing scientific insights into practical applications, making the benefits of anti-aging research accessible to a broader audience. | $572.5K / Pre-Seed / Jan 01, 2023 | |
Cyclone Therapeutics
|
Cyclone Therapeutics is a preclinical-stage drug discovery company spun out of The Scripps Research Institute. The company is focused on enhancing protein quality control by modulating translation, based on an anti-inflammatory 'integrated stress response mimetic' MoA. | Seed | |
Oisin Biotechnologies
|
Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age-related diseases. It is developing a highly precise, patent-pending, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces the negative effects of aging pathologies and alsoextends the median lifespan and survival.Oisin Biotechnologies was founded in 2014 and is headquartered in Seattle, Washington. | $10M / Series A |
Co-Investors
About Healthspan Capital
Healthspan Capital is a venture capital firm that invest and support longevity biotechnology companies.
Healthspan Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Sebastian Brunemeier
Co-founder & General Partner
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Sebastian Brunemeier invest in?
Sebastian Brunemeier invests primarily in Biotechnology, Medical and Wellness startups, most often at Seed and Pre-Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Sebastian Brunemeier last invest?
The most recent investment recorded for Sebastian Brunemeier closed in Jan 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
